What happened: A new drug called daraxonrasib has been shown to double the survival time for patients with pancreatic cancer, one of the deadliest cancers.
Why it matters:
- Improves prognosis for pancreatic cancer patients, who typically have low survival rates.
- Offers a new treatment option that could change current cancer management practices.
MNN Take: Daraxonrasib represents a significant advance by targeting pancreatic cancer more effectively, potentially extending patients’ lives beyond existing therapies.
Sources: BBC Health (Lifestyle)